Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Jul 16, 2025
Open Peer Review Period: Jul 30, 2025 - Sep 24, 2025
Date Accepted: Jan 5, 2026
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

WeChat-Based Intervention for Glycemic Control in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial

Zheng C, Dou X, Xiong X, Lei EY, Jiang M, Wu Y, Yu J, Wang X, Zhang L, Rong H, Lu L, Li F, Luo T, Ma X, Chen JA

WeChat-Based Intervention for Glycemic Control in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial

JMIR Mhealth Uhealth 2026;14:e80738

DOI: 10.2196/80738

PMID: 41719522

PMCID: 12923094

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

WeChat-Based Intervention for Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Multicenter Randomized Controlled Trial

  • Chuanfen Zheng; 
  • Xiong Dou; 
  • Xiaotao Xiong; 
  • En-Yu Lei; 
  • Ming Jiang; 
  • Yulin Wu; 
  • Jing Yu; 
  • Xianjun Wang; 
  • Ling Zhang; 
  • Honghui Rong; 
  • Lu Lu; 
  • Fengju Li; 
  • Ting Luo; 
  • Xiangyu Ma; 
  • Ji-An Chen

ABSTRACT

Background:

China’s diabetes epidemic faces critical gaps in glycemic control, with only 50.1% achieving HbA1c targets in 2021. Conventional interventions struggle with scalability in primary care, particularly for vulnerable populations.

Objective:

The study aimed to evaluate the WeChat-based health education tool (“WeWalk” mini program, “Bayu Health” public account and WeChat group) for improving glycemic control in community-dwelling T2DM patients.

Methods:

This multicenter randomized controlled trial enrolled 600 adults with type 2 diabetes from three Chongqing communities, randomly allocating participants 1:1 to either a 12-week WeChat-based intervention (n=300) or a control group (n=300) in September 2020. The control group received four face-to-face traditional health education sessions, while the intervention group participated in a digital program: a 4-week course (30 modules) followed by an 8-week practical implementation (60 behavioral tasks). At baseline and 12 weeks after the intervention began, both groups were examined in terms of HbA1c, fasting blood glucose (FBG) as the primary outcomes, as well as the variables such as blood lipid profile, blood pressure, physical fitness-related indices as secondary outcomes. Longitudinal glycemic control was assessed through triplicate FBG measurements extracted from standardized electronic health records at the 2-year follow-up. Independent t-tests or Mann-Whitney U tests were used to assess changes from baseline to follow-up between groups.

Results:

92.7% (556/600) of the participants completed the 12-week follow-up visit. The WeChat-based intervention demonstrated superior glycemic control outcomes, with intervention participants achieving a 0.59% greater HbA1c reduction compared to controls (-0.03% vs 0.56%; P<0.01) and significant FBG improvements (-0.69 vs 0.00 mmol/L, Δ=0.69, P<0.01). Subgroup analysis revealed that the WeChat-based health education was significantly effective in diabetic patients with a disease course of <10 years, education of junior high or below, and family income of <50,000 ¥/year. These benefits persisted through 2-year follow-up, where the intervention group maintained lower FBG levels (6.87 vs 7.35 mmol/L, P<0.01).

Conclusions:

The WeChat-based health education was beneficial for glycemic control in patients with T2DM in the primary health care settings. Furthermore, the long-term effects of the WeChat-based health education intervention need to be explored. Clinical Trial: Chinese Clinical Trial Registry ChiCTR2300071926.


 Citation

Please cite as:

Zheng C, Dou X, Xiong X, Lei EY, Jiang M, Wu Y, Yu J, Wang X, Zhang L, Rong H, Lu L, Li F, Luo T, Ma X, Chen JA

WeChat-Based Intervention for Glycemic Control in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial

JMIR Mhealth Uhealth 2026;14:e80738

DOI: 10.2196/80738

PMID: 41719522

PMCID: 12923094

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.